Dogwood Therapeutics (NASDAQ:DWTX) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Dogwood Therapeutics (NASDAQ:DWTX) announced its earnings results on Thursday. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07, Zacks reports.

Dogwood Therapeutics Trading Up 6.5%

Shares of NASDAQ:DWTX opened at $1.98 on Friday. Dogwood Therapeutics has a 52 week low of $1.28 and a 52 week high of $9.50. The company’s 50 day moving average is $2.12 and its two-hundred day moving average is $3.65. The company has a market cap of $66.13 million, a PE ratio of -0.10 and a beta of 1.68.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Dogwood Therapeutics in a research note on Monday, April 27th. Weiss Ratings downgraded shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $12.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 9.05% of the company’s stock.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.